血红蛋白与人血清白蛋白偶联物作为血液代用品的大鼠换血试验研究

 目的考察以血红蛋白与人血清白蛋白偶联物(Hb-HSA)及其他复苏液为大鼠换血后,大鼠血压变化及其长期存活率情况,研究此新型血液代用品的有效性。方法采用大鼠30%和60%换血两种模型,在线监测动脉血压,对比用Hb-HSA偶联产品、无基质血红蛋白、5%HSA溶液、Ringer乳酸盐溶液和原血换血以及失血不补液后大鼠血压变化,考察14d内大鼠的存活情况。结果大鼠30%换血,以扩容剂HSA和乳酸盐换血后,大鼠最终平均动脉血压(MAP)略低于初始值,无基质血红蛋白使MAP有所升高,Hb-HSA偶联产品与原血回输类似,基本维持原MAP。无基质血红蛋白,Hb-HSA偶联物和原血回输组大鼠存活率达100%,高于其他扩容剂换血实验组。大鼠60%换血,无基质血红蛋白及扩容剂HSA和乳酸盐换血后大鼠MAP仍然较低,Hb-HSA偶联产品基本能够维持MAP,类似于原血回输的对照,只有Hb-HSA偶联物换血和原血回输的大鼠100%存活。结论Hb-HSA偶联物为大鼠换血未引起血压升高,30%和60%换血后存活率均达100%,明显优于其他对照,体现出本偶联物对于紧急输血是一种具有优势的血液代用品。30%换血大鼠模型能够较好的体现出MAP因换血引起的波动,相对更适合于研究不同复苏液对血压的影响。

Replacement of rat blood with conjugate of hemoglobin and human serum albumin

OBJECTIVE To study the effect of replacement of rat blood with the conjugate of bovine hemoglobin and human serum albumin (Hb-HSA conjugate) and other resuscitation fluids on the blood pressure and survival. METHODS 30% or 60% of whole blood was replaced with Hb-HSA conjugate, ringer-lactate, solution, stroma-free hemoglobin (SFHb), 5% HSA in Ringer-lactate respectively. Whole blood replacement was used in blank control group and no resuscitation fluid was supplied in negative control group. Mean arterial pressure (MAP) was continuously recorded throughout the experiment. All rats were monitored for 14d. RESULTS For both 30% and 60% blood replacement, ringer-lactate and 5% HSA in ringer-lactate increased the MAP to a level lower than the baseline. Hb-HSA conjugate, the same as whole blood, maintains the MAP. While SFHb increased the MAP from (132.2±4.0)mmHg to (139.3±4.1)mmHg in 30% replacement group, but only sustained the blood pressure in the first 10 min and then decreased to lower level than the initial level in 60% replacement group. The Hb-HSA conjugate showed effectiveness with 100% survival rate (followed for 14 d), as well as whole blood replacement. CONCLUSION The pressure change in 30% bleeding rats is more sensitive to the resuscitation fluids. The Hb-HSA conjugate maintains the MAP of bleeding rats and effectively saved bleeding rats, prior to other resuscitation fluids. The results indicate that the product is able to be a candidate as blood substitute in emergency.